<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747303</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-1476</org_study_id>
    <nct_id>NCT02747303</nct_id>
  </id_info>
  <brief_title>Frameless Stereotactic Radiosurgery for Intact Brain Metastases</brief_title>
  <official_title>The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to determine if not treating planning target volume (PTV) margins
      during radiation therapy worsens progression free survival rates in patients with brain
      metastases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) rates estimated by the Kaplan-Meier method at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rates estimated by the Kaplan-Meier method</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rates</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of radiation necrosis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of pseudoprogression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local failure rates</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of late central nervous system (CNS) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2 and higher toxicities</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of distant intracranial failure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of salvage therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dose and risk of radionecrosis or pseudoprogression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery to 2 mm GTV to PTV margins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery to 0 mm GTV to PTV margins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)</description>
    <arm_group_label>Stereotactic Radiosurgery to 2 mm GTV to PTV margins</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery to 0 mm GTV to PTV margins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (≥ 18 years old) with an ECOG Performance Status 0-2 and a life
             expectancy of 3 months or more.

          -  Histologically confirmed systemic malignancy with gadolinium contrast-enhanced MRI
             scan demonstrating 1-5 intraparenchymal brain metastases.

          -  Well-circumscribed, measureable intraparenchymal brain lesion(s) with maximum tumor
             diameter ≤3.0 cm. If multiple lesions are present, the other(s) must not exceed 3.0 cm
             in maximum diameter. At least one lesion must be ≥1.0 cm in maximum diameter and ≥0.5
             cm in a perpendicular diameter to be considered measurable disease.

          -  Negative urine or serum pregnancy test done ≤ 14 days prior to CT simulation, for
             women of child-bearing potential only.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Diagnosis of germ cell tumor, small cell carcinoma or hematologic malignancy.

          -  Metastases in the brain stem, midbrain, pons, medulla, or within 7 mm of the optic
             apparatus (optic nerves, chiasm and optic tracts).

          -  Diagnosis of leptomeningeal disease.

          -  Prior cranial radiotherapy within 90 days of trial enrollment or prior SRS at any time
             to any lesion to be treated on protocol

          -  Chemotherapy (including oral agents and targeted agents) or immunotherapy given within
             14 days of SRS. Hormonal therapy is permitted. For Her2+ breast cancer patients,
             anti-Her2 therapy cannot be given within 14 days of SRS. Patients who are scheduled to
             receive trastuzumab emtansine after SRS cannot be enrolled.

          -  Contraindications to gadolinium contrast-enhanced MRI (eg, non-compatible pacemaker,
             eGFR&lt;30, gadolinium allergy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J. Chmura, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robyn Hseu</last_name>
    <phone>773-834-3198</phone>
    <email>rhseu@radonc.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Hseu</last_name>
      <email>rhseu@radonc.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Chmura, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastases</keyword>
  <keyword>Stereotactic Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

